首页 > 市场调查报告书 > 製药

再生医学细胞疗法

市场调查报告书

商品编码

1736602

同种异体干细胞移植市场：依来源、应用、最终用户、细胞类型和地区划分

Allogeneic Stem Cell Transplantation Market, By Source, By Application, By End User, By Cell Type, By Geography

出版日期: 2025年04月25日 | 出版商:

Coherent Market Insights | 英文 130 Pages | 商品交期: 2-3个工作天内

价格

简介目录

异体干细胞移植市场规模预计在 2025 年为 45.3 亿美元，预计到 2032 年将达到 76.6 亿美元，2025 年至 2032 年的复合年增长率为 7.8%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	45.3亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期：2025-2032年复合年增长率：	7.80%	2032年价值预测	76.6亿美元

图：2025年异体干细胞移植市场占有率（%），依地区划分

异体干细胞移植是一种将干细胞从捐赠者转移到接受者的医疗程序。这些干细胞可以从多种来源获取，包括骨髓、週边血和脐带血。移植的目的是透过用健康细胞取代受损或患病的细胞来恢復接受者器官和组织的功能。异体干细胞移植用于治疗多种疾病，包括癌症、遗传性疾病和某些免疫系统疾病。

全球异体干细胞移植市场正经历显着成长，原因是此类治疗方法可治癒的疾病日益增多。此外，移植技术的进步和新疗法的市场发展也进一步促进了市场的成长。市场的主要企业包括 Celgene Corporation、Mesoblast Ltd.、Pluristem Therapeutics Inc. 和工业株式会社。

市场动态：

可以透过影响市场的驱动因素、限制因素和机会来分析同种异体干细胞移植市场的市场动态。

驱动因素：白血病、淋巴瘤、多发性骨髓瘤等需要干细胞移植的疾病的发生率不断上升，是市场的主要驱动力。此外，老年人口的成长、移植技术的进步以及干细胞库数量的增加也推动了市场的成长。
限制因素：干细胞移植的高成本以及相关併发症（例如移植物抗宿主疾病）的风险是市场的主要限制因素。此外，某些地区对异基因干细胞移植潜在益处的认知度较低，也阻碍了市场的成长。
机会：创新治疗方法的开发和异体干细胞移植新应用的探索可能带来巨大的成长机会。此外，加大研发投入以及主要企业与研究机构之间的合作，也可望推动市场成长。

本研究的主要特点

本报告对全球异体干细胞移植市场进行了详细分析，包括预测期为 2025 年至 2032 年的市场规模和复合年增长率（假设 2024 年为基准年）。
它强调了各个细分市场中的潜在收益成长机会，并说明了该市场的引人注目的投资提案矩阵。
它提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的重要见解。
全球异体干细胞移植市场的关键参与者包括 Celgene Corporation、Mesoblast Ltd.、Pluristem Therapeutics Inc.、工业等，根据公司亮点、产品系列、关键亮点、财务绩效、策略等进行分析。
本报告将为负责人和经营团队提供有价值的讯息，使他们能够就未来的产品发布、市场扩张和行销策略做出明智的决策。
它迎合了行业中的各种相关人员，例如投资者、供应商、产品製造商、经销商、新进入者和财务分析师，并为决策提供见解。
相关人员可以从全球异体干细胞移植市场分析中使用的各种策略矩阵中受益，从而提高决策流程的便利性。

Celgene Corporation
Mesoblast Ltd.
Pluristem Therapeutics Inc.
MEDIPOST Co., Ltd.
Osiris Therapeutics, Inc.
Cynata Therapeutics Limited
Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
Cellular Biomedicine Group, Inc.
Biosolution Co., Ltd.
StemCell Technologies Inc.
Caladrius Biosciences, Inc.
TiGenix NV
ViaCord
Vericel Corporation
Regen Biopharma Inc.
Gamida Cell Ltd.
Histogenics Corporation
BrainStorm Cell Therapeutics Inc.
Lineage Cell Therapeutics, Inc.

第 11 章章节

调查方法
关于出版商

简介目录

Product Code: CMI6407

Allogeneic Stem Cell Transplantation Market is estimated to be valued at USD 4.53 Bn in 2025 and is expected to reach USD 7.66 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 7.8% from 2025 to 2032.

Report Coverage		Report Details
Base Year:	2024	Market Size in 2025:	USD 4.53 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	7.80%	2032 Value Projection:	USD 7.66 Bn

Figure. Allogeneic Stem Cell Transplantation Market Share (%), By Region 2025

Allogeneic Stem Cell Transplantation Market - IMG1

Allogeneic stem cell transplantation is a medical procedure that involves the transfer of stem cells from a donor to a recipient. These stem cells can be obtained from various sources such as bone marrow, peripheral blood, or umbilical cord blood. The aim of this procedure is to replace damaged or diseased cells with healthy ones, thereby restoring the function of the recipient's organs or tissues. Allogeneic stem cell transplantation has been used for the treatment of a wide range of conditions including cancers, genetic disorders, and certain immune system disorders.

The global allogeneic stem cell transplantation market is witnessing significant growth due to the increasing prevalence of diseases that can be treated through this procedure. Moreover, advancements in transplantation techniques, as well as the development of new therapeutic approaches, are further contributing to the market growth. The market is characterized by the presence of several key players including Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., and Takeda Pharmaceutical Company Limited, among others.

Market Dynamics:

The market dynamics of the allogeneic stem cell transplantation market can be analyzed through the drivers, restraints, and opportunities that shape the market.

Drivers: The increasing incidence of diseases that require stem cell transplantation, such as leukemia, lymphoma, and multiple myeloma, is a major driver for the market. Additionally, the growing geriatric population, advancements in transplantation techniques, and the rise in stem cell banking facilities are also fueling the market growth.
Restraints: The high costs associated with stem cell transplantation procedures and the risk of complications, such as graft-versus-host disease, act as significant restraints for the market. Moreover, the lack of awareness about the potential benefits of allogeneic stem cell transplantation in certain regions hinders the market growth.
Opportunities: The development of innovative therapies and the exploration of new applications for allogeneic stem cell transplantation present significant growth opportunities. Moreover, increasing investments in research and development activities and collaborations between key players and research institutions can drive the market growth.

Key Features of the Study:

This report provides an in-depth analysis of the global allogeneic stem cell transplantation market, including market size (US$ Bn) and Compound Annual Growth Rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It highlights potential revenue growth opportunities across different market segments and explains attractive investment proposition matrices for this market
The study offers key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key players in the global allogeneic stem cell transplantation market include Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., and Takeda Pharmaceutical Company Limited, and they are profiled based on company highlights, product portfolios, key highlights, financial performance, and strategies
The report provides valuable information to marketers and management authorities, enabling them to make informed decisions regarding future product launches, market expansion, and marketing tactics
It caters to various stakeholders in the industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts, providing them with insights for decision-making
Stakeholders can benefit from the various strategy matrices used in analyzing the global allogeneic stem cell transplantation market, enhancing ease in decision-making processes

Allogeneic Stem Cell Transplantation Market Segmentation:

By Source
- Bone Marrow
- Peripheral Blood
- Umbilical Cord Blood
- Adipose Tissue
- Dental Pulp
- Others
By Application
- Cancer
- Autoimmune Diseases
- Blood Disorders
- Cardiac Disorders
- Neurological Disorders
- Diabetes
- Others
By End User
- Hospitals
- Research Institutes
- Specialty Clinics
- Others
By Cell Type
- Allogeneic MSCs
- Allogeneic HSCs
- Others
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
Company Profiles:
- Celgene Corporation
- Mesoblast Ltd.
- Pluristem Therapeutics Inc.
- MEDIPOST Co., Ltd.
- Osiris Therapeutics, Inc.
- Cynata Therapeutics Limited
- Takeda Pharmaceutical Company Limited
- Astellas Pharma Inc.
- Cellular Biomedicine Group, Inc.
- Biosolution Co., Ltd.
- StemCell Technologies Inc.
- Caladrius Biosciences, Inc.
- TiGenix N.V.
- ViaCord
- Vericel Corporation
- Regen Biopharma Inc.
- Gamida Cell Ltd.
- Histogenics Corporation
- BrainStorm Cell Therapeutics Inc.
- Lineage Cell Therapeutics, Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Allogeneic Stem Cell Transplantation Market , By Source
- Allogeneic Stem Cell Transplantation Market , By Cell Type
- Allogeneic Stem Cell Transplantation Market , By Application
- Allogeneic Stem Cell Transplantation Market , By End User
- Allogeneic Stem Cell Transplantation Market , By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Rising incidence of chronic diseases
- Restraints
  - High costs associated with cell therapies
- Opportunities
  - Increasing use of allogeneic MSCs
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Allogeneic Stem Cell Transplantation Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Allogeneic Stem Cell Transplantation Market, By Source, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Bone Marrow
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Peripheral Blood
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Umbilical Cord Blood
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Adipose Tissue
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Dental Pulp
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)

6. Allogeneic Stem Cell Transplantation Market, By Cell Type, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Allogeneic MSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Allogeneic HSCs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

7. Allogeneic Stem Cell Transplantation Market, By Application, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Autoimmune Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Blood Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Cardiac Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Neurological Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Diabetes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

8. Allogeneic Stem Cell Transplantation Market, By End User, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Specialty Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Billion)

9. Allogeneic Stem Cell Transplantation Market, By Region, 2020-2032, (US$ Bn)

Introduction
- Market Share Analysis, By Region, 2023and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Source, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Cell Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
  - U.S.
  - Canada
Europe
Asia Pacific
Latin America
Middle East
Africa

10. Competitive Landscape

Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
Mesoblast Ltd.
Pluristem Therapeutics Inc.
MEDIPOST Co., Ltd.
Osiris Therapeutics, Inc.
Cynata Therapeutics Limited
Takeda Pharmaceutical Company Limited
Astellas Pharma Inc.
Cellular Biomedicine Group, Inc.
Biosolution Co., Ltd.
StemCell Technologies Inc.
Caladrius Biosciences, Inc.
TiGenix N.V.
ViaCord
Vericel Corporation
Regen Biopharma Inc.
Gamida Cell Ltd.
Histogenics Corporation
BrainStorm Cell Therapeutics Inc.
Lineage Cell Therapeutics, Inc.
Analyst Views

11. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

同种异体干细胞移植市场：依来源、应用、最终用户、细胞类型和地区划分